Share on StockTwits

Endocyte (NASDAQ:ECYT) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Monday. The firm currently has a $7.90 price objective on the stock. Zacks‘s price target indicates a potential upside of 17.91% from the stock’s previous close.

Endocyte (NASDAQ:ECYT) traded down 1.34% on Monday, hitting $6.61. 583,847 shares of the company’s stock traded hands. Endocyte has a one year low of $6.01 and a one year high of $33.70. The stock’s 50-day moving average is $6.5 and its 200-day moving average is $12.52. The company’s market cap is $274.3 million.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Friday, May 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The company had revenue of $17.30 million for the quarter, compared to the consensus estimate of $15.07 million. On average, analysts predict that Endocyte will post $-0.18 earnings per share for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Chardan Capital cut their price target on shares of Endocyte from $26.00 to $15.00 in a research note on Wednesday, June 18th. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital cut their price target on shares of Endocyte from $20.00 to $15.00 in a research note on Wednesday, June 18th. They now have an “outperform” rating on the stock. Finally, analysts at Citigroup Inc. initiated coverage on shares of Endocyte in a research note on Thursday, June 5th. They set a “neutral” rating and a $8.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $23.49.

Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.